ESMO Real World Data and Digital Oncology
Publisher: Elsevier · ISSN 2949-8201 · 100 articles
- 313eP AI-based evidence-grounded information extraction for automated risk assessment of hereditary breast and ovarian cancer from tumor board reports: A proof-of-concept study
- 314eP Oncology informatics in ireland & the National Cancer Information System (NCIS): A review on a national oncology EHR from the perspective of interoperability, health data sharing & molecular pathology digitalisation
- 315RO Can a clinical-purpose-LLM cover eligibility criteria changes in oncology trial amendments?
- 316P AI-powered translational genomics: Automated tumor cellularity assessment on H&E for tumor-enrichment decisions
- 317P A unified mathematical framework for latent-variable gene dependency modelling and network-based drug prioritization in precision oncology
- 318P OncoSAGE enables knowledge-guided drug prioritization for rare cancers
- 319P In silico AI-driven drug repositioning in precision oncology: Integrating graph neural networks and transcriptomics to overcome cancer resistance
- 320P APOD, a language-model agent that discovers population digital twins: Benchmark and application to platelet toxicity in radioligand therapy
- 321P HepSAFE: An integrated AI/ML platform to understand, translate, and predict clinical drug-induced liver injury
- 322P Patient Avatars predict clinical benefit from PI3Kδ inhibition and identify opportunities for indication expansion
- 323P Validation of machine-learning-assisted external control arms across phase III oncology trials: A leave-one-trial-out analysis of individual patient data
- 324P AI generated interventional protocols adherence to SPIRIT 2025: A blinded comparison of a clinical-purpose-LLM against general-purpose models
- 325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC)
- 326P Deletion of SASP cardiomyocytes with senolytic drugs conferred therapeutic effects in ICIs-related cardiotoxicity
- 327eP integrating molecular dynamics and AI for the development of HER2-targeted therapies in breast cancer
- 328eP Self-oxygenating PROTAC microneedles overcome immunotherapy resistance in non-small cell lung cancer
- 329eP Decoding cervical–endometrial cancer convergence through integrated network, immune and pharmacogenomic analysis
- 330eP Predicting neutropenia for antibody-drug conjugates unseen in training: Drug-antibody ratio versus payload class
- 331eP Delta-radiomics from screening and evaluation PET/CT in three phase I dose-escalation clinical trials of oncolytic adenovirus TILT-123
- 332RO DANTES, a deep learning attention-based framework integrating CT and [18F]FDG-PET foundation-model embeddings with clinical data for joint OS/PFS modelling
- 333P CASCADE: An agentic AI framework for trustworthy biomarker discovery in precision oncology
- 334P Local agentic vision-language models for zero-shot histopathology artifact detection
- 335P Investigating single-nucleus correspondence between H&E and imaging-based spatial transcriptomics incorporating alignment quality control in breast cancer
- 336P Artificial intelligence-based prediction of sequencing background noise for personalized NGS measurable residual disease monitoring
- 337P Generative flow matching models enable faithful counterfactual explanations of AI biomarker predictions
- 338P Positive control testing of drug response prediction models on TCGA patient tumors
- 339P AI-CROSS: Can artificial intelligence predict response to neoadjuvant chemoradiotherapy (CROSS) in gastro-oesophageal junction adenocarcinoma? A prospective randomized trial
- 340P From risk categories to individualized probability: A machine learning pipeline for recurrence prediction in differentiated thyroid cancer, with implications for resource-limited settings
- 341P Transported survival risk models in multicenter oncology: Separating unrecoverable transfers from method failure
- 342P Combining agentic AI and neuro-symbolic reasoning for clinical trial matching